NASDAQ:BCRX
BioCryst Pharmaceuticals Stock News
$4.57
+0.440 (+10.65%)
At Close: May 01, 2024
BioCryst to Report Third Quarter 2022 Financial Results on November 1
07:00am, Tuesday, 18'th Oct 2022
RESEARCH TRIANGLE PARK, N.C., Oct. 18, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its third quarter 2022 financial results Tue
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11:00am, Tuesday, 04'th Oct 2022 GlobeNewswire Inc.
RESEARCH TRIANGLE PARK, N.C., Oct. 04, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors gran
Got $3,000? Here Are 2 Stocks That Will Make You Richer
11:54am, Sunday, 02'nd Oct 2022 The Motley Fool
BioCryst Pharmaceuticals and Steris could both deliver outstanding returns for patient shareholders.
Got $3,000? Here Are 2 Stocks That Will Make You Richer
07:54am, Sunday, 02'nd Oct 2022
BioCryst Pharmaceuticals and Steris could both deliver outstanding returns for patient shareholders.
3 Biotech Stocks to Buy Now for Extraordinary Gains
09:16pm, Tuesday, 20'th Sep 2022
Biotech stocks have performed relatively well compared to the broader market of late. The SPDR S&P Biotech ETF (NYSEARCA: XBI ) is up 21% over the past three months compared with a 6% gain for the S&P
BioCryst Names Dr. Bill Sheridan Chief Development Officer and Appoints Dr. Ryan Arnold Chief Medical Officer
08:01pm, Wednesday, 14'th Sep 2022 GlobeNewswire Inc.
RESEARCH TRIANGLE PARK, N.C., Sept. 14, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. today announced that Dr. Bill Sheridan will become chief development officer and will focus on advanci
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11:00am, Tuesday, 06'th Sep 2022 GlobeNewswire Inc.
RESEARCH TRIANGLE PARK, N.C., Sept. 06, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors gra
BioCryst to Present at Upcoming Investor Conferences
08:01pm, Wednesday, 31'st Aug 2022 GlobeNewswire Inc.
RESEARCH TRIANGLE PARK, N.C., Aug. 31, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 2022 Wells Fargo Healthcare Confer
FDA Grants Orphan Drug Designation for BioCryst’s ALK-2 Inhibitor, BCX9250, for the Treatment of Fibrodysplasia Ossificans Progressiva
11:00am, Wednesday, 31'st Aug 2022 GlobeNewswire Inc.
RESEARCH TRIANGLE PARK, N.C., Aug. 31, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the U.S. Food and Drug Administration (FDA) has granted orphan drug des
BioCryst Presents Data Demonstrating >99 Percent Suppression of Alternative Pathway Complement Activity with BCX9930 in C3G Patients
11:00am, Friday, 26'th Aug 2022 GlobeNewswire Inc.
Study represents first data with BCX9930 in C3G patients Study represents first data with BCX9930 in C3G patients
U.S. Government Exercises Option to Purchase Additional RAPIVAB® (peramivir injection) from BioCryst for Pandemic Influenza Preparedness
11:00am, Thursday, 25'th Aug 2022 GlobeNewswire Inc.
RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the U.S. Department of Health and Human Services (HHS) has exercise
BioCryst Announces Approval of ORLADEYO® (berotralstat) in Saudi Arabia
11:00am, Thursday, 18'th Aug 2022 GlobeNewswire Inc.
RESEARCH TRIANGLE PARK, N.C., Aug. 18, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Saudi Food and Drug Authority (SFDA) has approved oral, once-d
Has Alignment Healthcare (ALHC) Outpaced Other Medical Stocks This Year?
01:40pm, Tuesday, 09'th Aug 2022 Zacks Investment Research
Here is how Alignment Healthcare (ALHC) and BioCryst Pharmaceuticals (BCRX) have performed compared to their sector so far this year.
Novavax, Upstart Holdings And Some Other Big Stocks Moving Lower In Today's Pre-Market Session
11:23am, Tuesday, 09'th Aug 2022 Benzinga
Novavax, Inc. (NASDAQ: NVAX) fell 30.7% to $39.70 in pre-market trading after the company reported second-quarter revenue decline of 37.6% year-over-year to $185.9 million. The company also lowered i
Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2022
02:10pm, Monday, 08'th Aug 2022 Benzinga
Upgrades
For iRobot Corp (NASDAQ:IRBT), JP Morgan upgraded the previous rating of Underweight to Neutral. In the second quarter, iRobot showed an EPS of $0.35, compared to $0.27 from the year-ago qua